Intellia presents positive data for hereditary angioedema treatment
LONDON - ANGLE plc has completed its name change to CelLBxHealth plc, with the new name officially registered at Companies House, according to a press release statement issued Wednesday.
The company’s stock ticker symbol on the London Stock Exchange will change from ANGLE to CLBX, effective from 8:00 a.m. today. The company’s ISIN and SEDOL identifiers will remain unchanged.
In conjunction with the rebranding, the company is also changing its website address to CelLBxHealth.com. Information required by AIM Rule 26 will be available on the "Investors" section of the angleplc.com website from 8:00 a.m. today.
The name change does not affect shareholders’ rights, and existing share certificates remain valid without requiring replacement.
The company first announced its intention to change its name on October 8, 2025.
CelLBxHealth describes itself as a precision circulating tumor cell (CTC) intelligence company that specializes in CTC solutions for research, drug development, and clinical oncology applications. The company’s main product is its Parsortix platform, which harvests CTCs from blood samples.
Dr. Jan Groen serves as Executive Chairman of CelLBxHealth, with Peter Collins as Interim CEO. Cavendish acts as the company’s nominated advisor and broker, while FTI Consulting handles its public relations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.